, La colistine en réanimation. Réanimation. 1 mai, vol.17, issue.3, pp.251-259, 2008.
Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models, Antimicrob Agents Chemother. mars, vol.54, issue.3, pp.1117-1141, 2010. ,
, U.I., poudre et solvant pour solution injectable -Base de données publique des médicaments
, Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clin Pharmacokinet, vol.56, issue.12, pp.1441-60, 2017.
Émergence de la résistance à la colistine chez les entérobactéries : une brèche dans le dernier rempart contre la panrésistance !, J Anti-Infect. 1 déc, vol.18, issue.4, pp.139-59, 2016. ,
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria, Antimicrob Agents Chemother. août, vol.53, issue.8, pp.3430-3436, 2009. ,
Structure-Activity Relationships of Polymyxin Antibiotics, J Med Chem. 11 mars, vol.53, issue.5, pp.1898-916, 2010. ,
Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: A narrative review for the clinician, J Infect. 1 juill, vol.69, issue.1, pp.1-12, 2014. ,
Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria, Bioconjug Chem. 16 avr, vol.25, issue.4, pp.750-60, 2014. ,
, , p.105, 2020.
L'antibiorésistance : pourquoi est-ce si grave ? ,
, , 2020.
La colistine en réanimation ,
,
,
Emergence of plasmidmediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study, Lancet Infect Dis. 1 févr, vol.16, issue.2, pp.161-169, 2016. ,
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients, Antimicrob Agents Chemother. juill, vol.55, issue.7, pp.3284-94, 2011. ,
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents, J Infect Chemother Off J Jpn Soc Chemother. mai, vol.21, issue.5, pp.319-348, 2015. ,
Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers, Clin Pharmacol Ther. juin, vol.89, issue.6, pp.875-884, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02472938
Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients, J Cyst Fibros. 1 mai, vol.19, issue.3, pp.421-427, 2020. ,
Colistin: the reemerging antibiotic for multidrug-resistant Gram-negative bacterial infections, Lancet Infect Dis. sept, vol.6, issue.9, pp.589-601, 2006. ,
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother. 1 déc, vol.70, issue.12, pp.3291-3298, 2015. ,
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models, J Antimicrob Chemother. sept, vol.65, issue.9, pp.1984-90, 2010. ,
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?, Clin Infect Dis Off Publ Infect Dis Soc Am. 1 mars, vol.62, issue.5, pp.552-560, 2016. ,
Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients, Antimicrob Agents Chemother, vol.24, 2017. ,
Nephrotoxicity Associated with Intravenous Colistin in Critically Ill Patients, Pharmacother J Hum Pharmacol Drug Ther, vol.31, issue.12, pp.1257-64, 2011. ,
High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 juin, vol.54, issue.12, pp.1720-1726, 2012. ,
Dosing guidance for intravenous colistin in critically-ill patients, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.01, issue.5, pp.565-71, 2017. ,
, Résumé des caractéristiques du produit -COLIMYCINE 1.000.000 U.I., poudre et solvant pour solution injectable -Base de données publique des médicaments
Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation, Réanimation. juin, vol.14, issue.4, pp.264-75, 2005. ,
Suivi thérapeutique pharmacologique des antifongiques : de l'intérêt des dosages, Mise Au Point, p.5 ,
Mécanismes de la résistance à la colistine chez les bactéries à gram négatif, vol.124, 2017. ,
, , 2020.
,
, QUELLES CONSÉQUENCES POUR L'ANESTHÉSISTE-RÉANIMATEUR, p.10
Prise en charge de la transplantation pulmonaire en réanimation, Réanimation. févr, vol.17, issue.1, pp.50-56, 2008. ,